provided that when X6 is N, then R^5 and R^6 are not hydrogen.

[0006] One embodiment provides a pharmaceutical composition comprising a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient. One embodiment provides a pharmaceutical composition comprising a compound of Formula (II), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

[0007] One embodiment provides a method of treating cancer in a patient in need thereof, comprising administering to the patient a compound of Formula (I), or a pharmaceutically acceptable salt thereof. One embodiment provides a method of treating cancer in a patient in need thereof, comprising administering to the patient a compound of Formula (II), or a pharmaceutically acceptable salt thereof.

[0007a] One embodiment provides the use of a compound of Formula (II) in the manufacture of a medicament for regulating gene transcription in a cell, wherein a bromodomain containing protein is exposed to the compound of Formula (II).

[0007b] One embodiment provides the use of a compound of Formula (II) in the manufacture of a medicament for inhibiting of bromodomain-mediated recognition of an acetyl lysine region of a protein, wherein the bromodomain is exposed to a compound of Formula (II).

[0007c] One embodiment provides the of a compound of Formula (II), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating cancer in a patient in need thereof.

[0007d] One embodiment provides the use of a compound as described herein in the manufacture of a medicament for regulating gene transcription in a cell, wherein a bromodomain containing protein is exposed to a compound as described herein.

[0007e] One embodiment provides the use of a compound as described herein in the manufacture of a medicament for inhibiting of bromodomain-mediated recognition of an acetyl lysine region, wherein the bromodomain is exposed to a compound as described herein.

[0007f] One embodiment provides the use of a compound as described herein, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating cancer in a patient in need thereof.

[0007g] One embodiment provides the use of a compound of Formula (I) in the manufacture of a medicament for regulating gene transcription in a cell, wherein bromodomain containing protein is exposed to the compound of Formula (I).

[0007h] One embodiment provides the use of a compound of Formula (I) in the manufacture of a medicament for inhibiting of bromodomain-mediated recognition of an acetyl lysine region of a protein, wherein the bromodomain is exposed to a compound of Formula (I).

[0007i] One embodiment provides the use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating cancer in a patient in need thereof.

INCORPORATION BY REFERENCE

[0008] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.

DETAILED DESCRIPTION OF THE INVENTION

[0009] As used herein and in the appended claims, the singular forms "a," "and," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "an agent" includes a plurality of such agents, and reference to "the cell" includes reference to one or more cells (or to a plurality of cells) and equivalents thereof known to those skilled in the art, and so forth. When ranges are used herein for physical properties, such as molecular weight, or chemical properties, such as chemical formulae, all combinations and subcombinations of ranges and specific embodiments therein are intended to be included. The term "about" when referring to a number or a numerical range means that the number or numerical range referred to is an approximation within experimental variability (or within statistical experimental error), and thus the number or numerical range may vary between 1% and 15% of the stated number or numerical range. The term "comprising" (and related terms such as "comprise" or "comprises" or "having" or "including") is not intended to exclude that in other certain embodiments, for example, an embodiment of any composition of matter, composition, method, or process, or the like, described herein, may "consist of" or "consist essentially of" the described features.

Definitions

yl]ethanesulfonamide;

5-(5-butyl-2-methylsulfonylpyrimidin-4-yl)-1-methyl-3-propan-2-ylpyridin-2-one;

N-[5-(2,4-difluorophenoxy)-4-(1-methyl-6-oxo-5-propan-2-ylpyridin-3-yl)pyrimidin-2-yl]ethanesulfonamide; or

5-[5-(2,4-difluorophenoxy)-2-methylsulfonylpyrimidin-4-yl]-1-methyl-3-propan-2-ylpyridin-2-one.

70. A pharmaceutical composition comprising a compound of Formula (II), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

71. ~~A method of regulating gene transcription in a cell comprising exposing a bromodomain-containing protein to~~ Use of a compound of Formula (II) in the manufacture of a medicament for regulating gene transcription in a cell, wherein a bromodomain containing protein is exposed to the compound of Formula (II).

72. ~~A method of inhibiting of bromodomain-mediated recognition of an acetyl-lysine region of a protein comprising exposing the bromodomain to~~ Use of a compound of Formula (II) in the manufacture of a medicament for inhibiting of bromodomain-mediated recognition of an acetyl lysine region of a protein, wherein the bromodomain is exposed to a compound of Formula (II).

73. ~~A method of treating cancer in a patient in need thereof, comprising administering to the patient~~ Use of a compound of Formula (II), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating cancer in a patient in need thereof.

74. A pharmaceutical composition comprising a compound of claim 69, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

75. ~~A method of regulating gene transcription in a cell comprising exposing a bromodomain-containing protein to~~ Use of a compound of claim 69 in the manufacture of a medicament for regulating gene transcription in a cell, wherein a bromodomain containing protein is exposed to a compound of claim 69.

76. ~~A method of inhibiting of bromodomain-mediated recognition of an acetyl-lysine region of a protein comprising exposing the bromodomain to~~ Use of a compound of claim 69 in the manufacture of a medicament for inhibiting of bromodomain-

mediated recognition of an acetyl lysine region, wherein the bromodomain is exposed to a compound of claim 69.

77. ~~A method of treating cancer in a patient in need thereof, comprising administering to the patient~~ Use of a compound of claim 69, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating cancer in a patient in need thereof.

78. ~~A method of regulating gene transcription in a cell comprising exposing a bromodomain containing protein to~~ Use of a compound of Formula (I) in the manufacture of a medicament for regulating gene transcription in a cell, wherein bromodomain containing protein is exposed to the compound of Formula (I).

79. ~~A method of inhibiting of bromodomain-mediated recognition of an acetyl lysine region of a protein comprising exposing the bromodomain to~~ Use of a compound of Formula (I) in the manufacture of a medicament for inhibiting of bromodomain-mediated recognition of an acetyl lysine region of a protein, wherein the bromodomain is exposed to a compound of Formula (I).

80. ~~A method of treating cancer in a patient in need thereof, comprising administering to the patient~~ Use of a compound of Formula (I), or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating cancer in a patient in need thereof.